secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001193125-24-188277
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition
--------------------------------------------------------------------------------

- Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.
- Book-to-bill 1.02 for quarter; orders $157M; new modalities sales up 5% YoY.
- CEO Tony Hunt becomes Executive Chair; Olivier Loeillot appointed President & CEO effective Sept 1.
- Post-quarter-end, entered agreement to acquire chromatography innovator Tantti Laboratory Inc. (value undisclosed).
- FY 2024 revenue guidance narrowed to $620-635M; adjusted EPS guidance unchanged at $1.42-1.49.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312524188277/0001193125-24-188277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312524188277/d848995d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-188277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer